PRINCETON, N.J.– 3월 29, 2021 –Certara, Inc. 글로벌 바이오시뮬레이션 선두기업(Nasdaq: CERT), a global leader in biosimulation, today announced the closing of its underwritten public offering of 11,500,000 shares of its common stock by certain existing stockholders at a public offering price of $25.00 per share. The closing includes 1,500,000 shares sold upon full exercise of the underwriters’ … Continued
PRINCETON, N.J.—3월 24, 2021. Certara, Inc. 글로벌 바이오시뮬레이션 선두기업(Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders (“the selling stockholders”) at a price to the public of $25.00 per share. Additionally, the selling stockholders have granted the underwriters … Continued
PRINCETON, N.J.—3월 22, 2021. Certara, Inc. (“Certara”), a global leader in biosimulation, today announced a proposed underwritten public offering of 17 million shares of its common stock being offered by selling stockholders. Additionally, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to 2,550,000 additional shares of common stock. Certara … Continued
PRINCETON, N.J.—Mar. 11, 2021– Certara, Inc. 글로벌 바이오시뮬레이션 선두기업(Nasdaq: CERT), a global leader in biosimulation, today announced that it is set to join the Russell 1000® Index, effective after the U.S. market open on 3월 22, 2021, according to a preliminary list of quarterly IPO additions posted 2월 26, 2021. The Russell 1000® Index measures the performance … Continued
Year-over-year 2020 revenue grew 17% to $243.5 million Raised $768.5 million in gross IPO proceeds for the Company and selling stockholders PRINCETON, N.J.—Mar. 4, 2021– Certara, Inc. 글로벌 바이오시뮬레이션 선두기업(Nasdaq: CERT), a global leader in biosimulation, today reported its preliminary results for the fourth quarter and full year ended 12월 31, 2020. Highlights: Revenue was $64.6 million … Continued
PRINCETON, N.J.—Feb. 26, 2021– Certara, Inc. 글로벌 바이오시뮬레이션 선두기업(Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, CEO and Andrew Schemick, CFO will virtually present at the Barclays Global Healthcare Conference on 2021년 3월 09일 화요일 at 11:30 a.m. ET. A live webcast will be available on Certara’s investor relations website at https://ir.certara.com and … Continued
PRINCETON, N.J.—Feb. 17, 2021– Certara, Inc. 글로벌 바이오시뮬레이션 선두기업(Nasdaq: CERT), a global leader in biosimulation, today announced that it will release preliminary financial results for the fourth quarter and full year of 2020 after the market close on 2021년 3월 04일 목요일. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. … Continued
PRINCETON, NJ.— 12월 16, 2020 – Certara, Inc. (“Certara”), a global leader in biosimulation by 2019 revenue, today announced that on 12월 15, 2020, it closed its upsized initial public offering of 33,413,250 shares of common stock at $23.00 per share. The closing includes 4,358,250 shares sold upon full exercise of the underwriters’ option to … Continued
PRINCETON, NJ.— 12월 10, 2020 – Certara, Inc. (“Certara”), a global leader in biosimulation, today announced the pricing of its upsized initial public offering of 29,055,000 shares of its common stock at $23.00 per share. Certara is offering 14,630,000 shares of its common stock and certain selling stockholders are offering 14,425,000 shares of common stock … Continued
PRINCETON, NJ.— 12월 3, 2020 – Certara, Inc. (“Certara”) today announced the launch of its initial public offering of 24,390,000 million shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission. Certara is offering 14,630,000 shares of common stock and certain selling stockholders are offering 9,760,000 shares of … Continued
